THCV

THCV's dose-dependent pharmacology complicates risk stratification for individuals with psychotic disorders. At low doses, 5-HT1A receptor agonism produces antipsychotic-like effects in preclinical models. At high doses where CB1 partial agonism emerges, THC-like psychotomimetic effects could theoretically occur. The dose at which this transition happens in humans is unknown.

No THCV-specific hepatic safety data exist. THCV is expected to undergo hepatic CYP2C9/CYP3A4 metabolism based on cannabinoid class pharmacology. Significant hepatic impairment could alter THCV clearance and increase exposure to uncharacterized levels. The Δ8-THCV analogue was hepatoprotective (not hepatotoxic) in mouse ischaemia/reperfusion models.

Insulin therapy, Sulfonylurea therapy

The Jadoon 2016 RCT demonstrated THCV reduces fasting plasma glucose and improves β-cell function when added to metformin. Combination with insulin or sulfonylureas — which lower glucose through different mechanisms — could theoretically increase hypoglycemia risk. This was not specifically reported in the metformin co-administration trial but is inferred from the additive pharmacological profiles.

No reproductive toxicity data have been published for THCV. Contraindicated based on general cannabinoid class principles — the endocannabinoid system plays critical roles in embryonic implantation, placentation, and fetal neurodevelopment — and the complete absence of safety data in this population.

Warfarin, Phenytoin, HMG-CoA reductase inhibitors (certain statins), Other narrow TI CYP2C9/CYP3A4 substrates

No in vitro CYP inhibition or induction data for THCV have been published. THCV's potential to alter the metabolism of co-administered drugs is entirely uncharacterized. Co-administration with narrow therapeutic index drugs metabolized by CYP2C9 or CYP3A4 warrants caution until interaction studies are conducted.